JULIUS CLINICAL – WHO WE ARE TODAY
Science forms the basis of all we do. Our internationally recognised academic leaders are actively involved in the design, conduct, and interpretation of clinical trials. This scientific expertise and credibility combined with operational excellence means that we are uniquely equipped to assist in providing answers for today’s clinical drug development challenges.
What we offer are end-to-end CRO services in specific therapeutic areas based on our scientific expertise. But we are also able to manage all aspects of sites – from selection of sites to administration.
We work with independent scientists supporting peer to peer approach of investigators.
Cooperating closely with key opinion leaders to support scientific oversight and decide on the optimal operational model is how we work. We established Scientific Networks to better recruit patients. Our scientists formulate research questions and ideas that we present to a Sponsor.
Due to the way we are structured and our willingness to look at innovative solutions, we have the ability and flexibility to react to changes in requirements very quickly. We are able to look beyond process to address the real issues that matter, and work with our site networks and clinical research experts to provide tailor-made, cost effective proposals addressing the needs of Biotech and Pharmaceutical companies, as well as Investigators sponsoring a trial.
Julius Clinical is specialized in distinct therapeutic areas including Alzheimer’s disease, Amyotrophic Lateral Sclerosis, Ear Nose Throat, Vaccines, Respiratory Syncytial Virus, Nonalcoholic Steatohepatitis, Dyslipidemia, and Real World Evidence. We can offer a full-service proposal or separate functional services as required. Our expertise ranges from early phase to post-registration, and we advocate the use of RWE if this enhances the outcome of the project.
Our collaborative approach has led to many long-standing relationships with a reputed client base.
WHERE WE COME FROM
Julius Clinical was founded in 2008 as a spin-off from the clinical project unit of the Julius Center for Health Sciences and Primary Care a part of the University Medical Center (UMC) Utrecht. The Julius Center and Julius Clinical are both named after the same professor of health sciences: Henri Willem Julius (1901-1977). Julius devoted his career to medical education and modern research methodology. He was one of the first to recognise the importance of and need for randomised trials. Julius Clinical’s culture of continuous learning and innovation closely resembles his goals and aspirations.
Fewer than thirty people worked at Julius Clinical in 2008 and we now have 140. While our size may be viewed as negative by some, we see it as a strength: we have the ability to react to changes in requirements very quickly and this flexibility gives us a competitive advantage over our larger competitors.